Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: Current concepts

Ulcerative colitis and Crohn's disease both confer an increased risk of developing colorectal cancer. The use of 5‐aminosalicylate as a remission‐inducing agent has been long accepted. Its use as a potential chemoprophylactic agent has been proposed and is used by some practitioners. This revie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2007-10, Vol.13 (10), p.1293-1298
Hauptverfasser:	Levine, Jonathan S., Burakoff, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	5‐ASA 6-Mercaptopurine Anti-Inflammatory Agents, Non-Steroidal - therapeutic use azathioprine Azathioprine - therapeutic use Cholagogues and Choleretics - therapeutic use Colorectal cancer Colorectal Neoplasms - etiology Colorectal Neoplasms - prevention & control Crohn's disease Data processing Folic acid Folic Acid - therapeutic use Humans Immunosuppressive Agents - therapeutic use inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - complications Inflammatory Bowel Diseases - drug therapy Intestine Mercaptopurine - therapeutic use Mesalamine - therapeutic use Reviews Treatment Outcome Ulcerative colitis ursodeoxycholic acid Ursodeoxycholic Acid - therapeutic use Vitamin B Complex - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ulcerative colitis and Crohn's disease both confer an increased risk of developing colorectal cancer. The use of 5‐aminosalicylate as a remission‐inducing agent has been long accepted. Its use as a potential chemoprophylactic agent has been proposed and is used by some practitioners. This review examines the most recent data on 5‐aminosacilycylate as a chemoprophylactic drug as well as ursodeoxycholic acid, folic acid, azathioprine, and 6‐mercaptopurine. (Inflamm Bowel Dis 2007)
ISSN:	1078-0998 1536-4844
DOI:	10.1002/ibd.20186